Drug targets imaging – the core of modern biomedical science and clinical diagnostics – holds secrets about the biology of disease, treatment and drug design. It can measure molecular and cellular behaviour, at scale, so that we can understand the pathophysiology better and then precisely target interventions. The subject of this blog is drug targets imaging philosophies, techniques, and application and the revolution that has occurred in medicine.

Figure 1. Applications of imaging during drug discovery and development. (Kelloff GJ, et al.; 2005)

Principles of Drug Targets Imaging

Drug targets imaging relies on mixing and matching imaging techniques to see molecular targets of disease. Those could be proteins, nucleic acids or pathogenic biomolecules. Such targets would be imaged and mapped using the imaging probes or probes that they would stick to.

The most common imaging techniques for drug targets imaging are:

1. Magnetic Resonance Imaging (MRI): Extracts image from soft tissue with high magnetic field and radio waves. The MRI contrast agents (often comprised of gadolinium or iron oxide nanoparticles) are also flexible enough to go after biomolecules.
2. Positron Emission Tomography (PET): Radioactive tracer (such as fluorodeoxyglucose (FDG) which releases positrons as it decays). These tracers can be slid on to target molecules to show the cellular/molecular process at work.
3. Computed Tomography (CT): Combines X-ray angles taken to create cross-sectional images. Contrast agents can be injected that mimic iodine to help bring out particular tissues or organs.
4. Optical Imaging: Involve fluorescence or bioluminescence to see biological phenomena in molecular scale. Imaging agents are frequently fluorescent dyes and proteins, including green fluorescent protein (GFP).
5. Ultrasound Imaging: Uses very high frequencies of sound waves to create images of soft tissue. Microbubble contrast can be targeted to biomarkers for high image resolution.

Methodologies in Drug Targets Imaging

Development of drug targets imaging includes these steps:

1. Target Identifying: The first is to identify potential molecular targets that are part of the disease process. That's usually by carrying out extensive studies to discover the molecular kinetics of the disease.
2. Imaging Probes Design and Synthesis: Imaging probes can bind to targeted targets selectively. This is a complicated affair and depends on the probe chemical makeup, binding ability and stability. The probes might be molecules, peptides, antibodies or nanoparticles.
3. Imaging Probes In vitro Validation: Imaging probes should be tested in vitro for specificity and binding ability prior to in vivo application. This comes mainly in the form of enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and cell-based tests.
4. Vivo Imaging: Once the probes are in vitro validated, they are compared in animals. This is done by introducing the probe to the animal and imaging the target with the appropriate imaging device.
5. Clinical Translation: The success of the in vivo imaging studies can also be translated into clinical trials where the probes are tested in human patients to assess safety, efficacy and diagnostic value.

Our Services

Imaging Analysis for Drug Discovery & Development

Applications of Drug Targets Imaging

This is the spectrum of drug targets imaging applications in research and in practice:

1. Disease Diagnoses and Prognosis: Identifying and staging disease, including cancer, heart disease and neurodegenerative disease early on by the use of images. In PET scans with FDG, for example, metabolic rate is seen in tumours and can help diagnose and classify cancer.
2. Treatment Tracking: Diagnostic imaging can be used to track the success of therapy treatment in real time. MRI, for example, can record tumor volume and blood flow after chemotherapy, and this information is useful for treatment effectiveness.
3. Drug Development: Drug targets imaging is also very useful in drug development pipeline, for drug-target interactions, biodistribution, and pharmacokinetic analysis. This data is invaluable for better drug design and dosage.
4. Personalized Medicine: Imaging can tailor treatments to a patient by determining the molecular features of the disease. It's a practice called precision medicine, which improves treatment and diminishes side-effects.
5. Disease Mechanisms: Imaging is a tool for understanding how diseases function, by mapping molecular and cellular events directly in vivo. This information can lead to new targets and treatment interventions.

Future Perspectives and Challenges

The future for drug targets imaging looks rosy as probe design, imaging and data processing continues to improve. New imaging probes that are more specific, sensitivity and multiplexing are being designed that can show multiple targets at the same time. As the system is integrated with other technologies (eg, AI, machine learning), the ability to extract insight from imaging data will continue to grow.

However, several challenges remain. Imaging probes that are clinically useful take a long time to create, and require much validation and regulatory approval. Even the cost of imaging technology and services can inhibit access in low-resource environments.

Even with these limitations, there's no denying the importance of drug targets imaging in healthcare. By allowing the atomically precise visualization of disease processes and treatments, imaging is changing how diseases are diagnosed, managed and understood. Further research and development, along with joint work between academia, industry and health care providers, will be necessary to make this exciting technology fully utilized.

Drug targets imaging, therefore, is the next big step in biomedical science and it promises to reveal the molecular foundations of disease and the effectiveness of therapeutic treatments like never before. With the technology evolving, however, its use will no doubt make medical care more individualized, efficient and responsive, leading to better patient outcomes and expanding the limits of medical research.

1. Kelloff GJ, et al.; The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005, 11(22):7967-85.

*If your organization requires the signing of a confidentiality agreement, please contact us by email.

Please note: Our services can only be used for research purposes. Do not use in diagnostic or therapeutic procedures!